Stock Movers Novo Nordisk Falls, State Street Drops, Zions Plunges on Losses From Alleged Fraud On this episode of Stock Movers:
Oct 17, 2025
Shares of Novo Nordisk tumble after President Trump's comments on lowering Ozempic prices spark concerns. State Street faces investor anxiety as its net interest income misses expectations, despite an earnings beat. Meanwhile, Zion and Western Alliance see their stocks plunge due to fraud revelations related to commercial-loan investments. The market reacts sharply, highlighting the ongoing turbulence in the financial sector.
AI Snips
Chapters
Books
Transcript
Episode notes
Ozempic Price Claim Sparks Market Drop
- President Trump said Ozempic could drop to about $150 monthly from roughly $1,000 list price, pressuring Novo Nordisk shares.
- Bloomberg analysts warn implementation is complex and market reaction may be a knee-jerk selloff.
State Street Hurt By Net Interest Income Miss
- State Street beat adjusted EPS but missed net interest income expectations, triggering investor concern.
- Analysts flag that low NII guidance contrasts with peers and may weigh on shares despite fee growth.
Zions' Losses Seem Idiosyncratic
- Zions' sharp selloff appears tied to charge-offs on two specific commercial loans and possible fraud, not broad credit deterioration.
- Analysts view the risk as idiosyncratic and note overall asset quality and small-business lending remain solid.
